Proactive Promotional Activities and Acquisition of Large-Scale Projects
First written in FY2016-Q4. 18 of 33 entries say "Restated". Latest entry: FY2026.
Human Metabolome Technologies moved to the "Worse" side of this theme in 2026, 5 years after the typical company in this theme (2021).
9 other companies' latest entry also says "Reframed".
- FY2026Transformation from an order-responsive sales model to a sales model that creates latent demand.Annual report
「Until now, sales have often followed an order-responsive style and have remained dependent on individual sales representatives in some respects. To expand corporate projects going forward, it is necessary to shift to a sales style that creates latent needs among corporate customers and to codify it as a reproducible organisational framework. The Group will also work to improve sales efficiency by making full use of data and AI.」
It explicitly stated that the Group will shift from conventional promotional activities and the acquisition of large projects to a sales style that creates latent needs among corporate customers, while improving sales efficiency through the use of data and AI. - 2026-08-20ReframedFinancial results briefing materials
「Sales process reform Individual-dependent sales Intuition and experience Order-response model Repeatable sales Data and AI Latent-needs creation model」
The company specified a shift from continuing conventional sales activities to reforming the sales process around repeatable, data- and AI-driven sales that create latent demand. - FY2025-H1AdvancedAnnual report
「Sales in the academic sector increased due to advance orders and other factors. Sales in the food and pharmaceutical sectors also increased as a result of securing large projects, leading to a significant increase in overall domestic sales.」
Continued sales activities for highly sensitive comprehensive analysis services and, by securing advance orders and large projects in the domestic academic, food and pharmaceutical sectors, significantly increased domestic sales. - FY2024RestatedAnnual report
「The Group worked to expand orders in its advanced research and development support business, centred on highly sensitive comprehensive analysis services, and its healthcare solutions business, centred on comprehensive support services for functional-materials development.」
Continues sales and promotional activities and efforts to expand orders centred on highly sensitive comprehensive analysis services and comprehensive support services for functional-materials development. - FY2024-Q3RestatedAnnual report
「Against this backdrop, the Group worked to expand orders in its healthcare solutions business, centred on its advanced research and development support business and comprehensive support services for functional-materials development, by conducting energetic sales activities for highly sensitive comprehensive analysis services.」
Continues efforts to expand orders through sales activities for highly sensitive comprehensive analysis services. - FY2024-Q2RestatedAnnual report
「The Group worked to expand orders in its healthcare solutions business, centred on its advanced research and development support business and comprehensive support services for functional-materials development, by conducting energetic sales activities for highly sensitive comprehensive analysis services.」
Continues efforts to conduct sales activities and expand orders centred on highly sensitive comprehensive analysis services. - FY2024-Q1WorsenedAnnual report
「In this business segment, highly sensitive comprehensive analysis services performed steadily in Japan. In Europe and the US, however, revenue declined because there were no projects comparable to the large-scale and customised projects recorded in the same period of the previous year.」
Although the Group advanced sales activities and order expansion for highly sensitive comprehensive analysis services, revenue in Europe and the US declined because there were no projects comparable to the large-scale and customised projects in the same period of the previous year. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Group worked vigorously to sell high-sensitivity comprehensive analysis services for metabolites, thereby seeking to expand orders in the Advanced Research and Development Support Business, while continuing to reduce general and administrative expenses excluding research and development expenses.」
Continues measures to expand orders through sales activities for highly sensitive comprehensive analysis services and reduce general and administrative expenses. - FY2023-Q1RestatedAnnual report
「The Group worked to expand orders in its advanced research and development support business by conducting energetic sales activities for highly sensitive comprehensive analysis services, while continuing to reduce general and administrative expenses excluding research and development expenses.」
Continues sales activities and order expansion for highly sensitive comprehensive analysis services, as well as reductions in general and administrative expenses. - FY2022AdvancedAnnual report
「Against this backdrop, the Group worked to expand orders in its advanced research and development support business by conducting energetic sales activities using the Web. By expanding sales of its high-value-added, highly sensitive comprehensive analysis services, orders increased substantially, accompanied by an increase in sales.」
It was stated that continued Web-based sales and the expansion of sales of highly sensitive comprehensive analysis services resulted in increases in order intake and revenue. - FY2022-Q3AdvancedAnnual report
「Against this backdrop, the Group sought to expand orders in the Advanced Research and Development Support Business, formerly the metabolomics business, through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. These activities led to a substantial increase in orders from October of the previous year, and the Group achieved its highest-ever revenue for a third quarter cumulative consolidated period.」
Continued Web-based sales activities, improved sales efficiency and reduced general and administrative expenses led to a substantial increase in orders from October last year onward and record-high cumulative revenue. - FY2022-Q2AdvancedAnnual report
「Against this backdrop, the Group worked to expand orders in its advanced research and development support business, formerly called the metabolomics business, by conducting energetic sales activities using the Web, while also working to improve sales efficiency and reduce general and administrative expenses.」
It was stated that continued Web-based sales activities, improved sales efficiency and reduced general and administrative expenses led to a substantial increase in orders from October onward. - FY2022-Q1WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the Advanced Research and Development Support Business, formerly the metabolomics business, through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. Although most of the first quarter was under a state of emergency, orders remained steady. However, revenue for the first quarter cumulative consolidated period declined substantially year on year because measurement samples were delayed under the state of emergency and for other reasons.」
Although the Group continued sales activities and measures to expand orders, deterioration in sales was reported due to delays in obtaining measurement samples and other factors. - FY2021WorsenedAnnual report
「Against this backdrop, the Group worked to expand orders in its metabolomics business by conducting energetic sales activities using the Web, while also working to improve sales efficiency and reduce general and administrative expenses.」
Although the Group continued promotional activities, including Web-based sales, orders declined year on year due to delays in research plans, including large-scale human studies. - FY2021-Q3WorsenedAnnual report
「Against this backdrop, the Group sought to expand orders in the metabolomics business through vigorous sales activities using the web, while also working to improve sales efficiency and reduce general and administrative expenses. However, during the third quarter consolidated accounting period, both orders and sales declined because scheduled orders were postponed and measurement samples were delayed, resulting in lower revenue for the third quarter cumulative consolidated period as well.」
Although the Group continued sales activities aimed at expanding orders, it was stated that orders and sales declined due to the postponement of scheduled orders and other factors. - FY2021-Q2AdvancedAnnual report
「In this business segment, the Group conducted sales activities centred on the use of the Web. As a result, sales increased significantly in the domestic academic sector and in the overseas US pharmaceutical sector.」
It was stated that sales increased in the domestic academic sector and the overseas US pharmaceutical sector through sales activities centred on the use of the Web. - FY2021-Q1AdvancedAnnual report
「In this business segment, the Group conducted sales activities centred on the use of the Web. As a result, sales increased significantly in the domestic food sector and in the overseas US pharmaceutical sector. Consequently, revenue was ¥244.837 million, up 23.8% year on year, and segment profit was ¥60.608 million, up 91.3% year on year.」
It was stated that the Group conducted sales activities centred on the use of the Web, increasing sales in the domestic food sector and the overseas US pharmaceutical sector, with segment revenue up 23.8% and segment profit up 91.3%. - FY2020AdvancedAnnual report
「In this business segment, sales increased in all fields as the Group conducted active promotional activities, including reviewing its sales strategy and strengthening its sales organisation, and worked to expand orders for large projects.」
It was stated that the Group expanded orders for large projects and increased sales in all fields through a review of its sales strategy, strengthening of its sales organisation and active promotional activities. - FY2020-Q3AdvancedAnnual report
「In this business segment, the Group continued its active promotional activities from the previous fiscal year and worked to expand orders for large projects. As a result, sales increased across all fields compared with the corresponding period of the previous year, 1 July 2018 to 31 March 2019. The Group also reviewed its sales strategy and worked to strengthen its sales structure.」
Continues active promotional activities and the expansion of orders for large projects. Sales increased in all fields, while the Group is also reviewing its sales strategy and strengthening its sales organisation. - FY2020-Q2RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food, chemical and other fields, and reviewed its sales strategy and worked to strengthen its sales organisation.」
Continues to conduct active promotional activities, expand orders for large projects, review its sales strategy and strengthen its sales organisation. - FY2020-Q1RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and reviewed its sales strategy and worked to strengthen its sales organisation.」
Continues active promotional activities and the acquisition of large projects in the pharmaceutical, food and other fields, while also reviewing its sales strategy and strengthening its sales organisation. - FY2019RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for new services launched in April and October 2018.」
Continues promotional activities, the expansion of orders for large projects and the acquisition of orders for new services. - FY2019-Q3RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for new services launched in April and October 2018.」
Continues to conduct active promotional activities, expand orders for large projects and secure orders for new services. - FY2019-Q2RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for new services launched in April and October 2018.」
Continues to conduct active promotional activities, expand orders for large projects and secure orders for new services. - FY2019-Q1RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for a new service launched in April 2018.」
Continues to conduct active promotional activities, expand orders for large projects and secure orders for the new service launched in April 2018. - FY2018-Q4RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical, food and other fields, and focused on securing orders for a new service launched in April 2018.」
Continues to conduct active promotional activities, expand orders for large projects and secure orders for new services. - FY2018-Q2RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the chemical, pharmaceutical and other fields, and promoted research and development activities aimed at expanding the lineup of analytical services.」
Continues to conduct active promotional activities, expand orders for large projects and pursue research and development aimed at expanding the lineup of analytical services. - FY2018-Q1RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the chemical, pharmaceutical and other fields, and strengthened its organisational structure and equipment to develop new services.」
Continues active promotional activities and the acquisition of large projects in the chemical, pharmaceutical and other fields. Strengthening the organisational structure and equipment is stated as a measure related to new service development. - FY2017-Q4RestatedAnnual report
「In this business segment, the Group continued to conduct active promotional activities, as in the previous fiscal year, worked to expand orders for large projects in the pharmaceutical and other fields, and promoted the development of new services.」
Continues to conduct active promotional activities, expand orders for large projects and develop new services. - FY2017RestatedAnnual report
「In this business segment, the Group continued its active promotional activities from the previous fiscal year and worked to acquire large projects, while focusing on cultivating new markets, including those related to foods with function claims.」
Continues to conduct active promotional activities, secure large projects and develop new markets. - FY2017-Q2RestatedAnnual report
「In this business segment, the Group continued its active promotional activities from the previous fiscal year and worked to acquire large projects, while focusing on cultivating new markets, including those related to foods with function claims.」
Continues to state that it is conducting active promotional activities, securing large projects and developing new markets. - FY2017-Q1RestatedAnnual report
「As in the previous fiscal year, the Group conducted active promotional activities and worked to acquire large projects, while focusing on cultivating new markets, including those related to foods with function claims.」
As in the previous fiscal year, the Group continued active promotional activities, acquisition of large projects and cultivation of new markets. - FY2016-Q4First statedAnnual report
「As in the previous fiscal year, the Group conducted active promotional activities and worked to acquire large projects, while focusing on cultivating new markets, including those related to foods with function claims.」
The company identified promotional activities, such as exhibiting at academic conferences and running campaigns, and acquiring large projects as specific measures.